Press Releases

Press Releases

January 10, 2022
CERPASS clinical trial with RP1 in CSCC on track to complete enrollment mid-year with the primary analysis trigger six months thereafter IGNYTE anti-PD1 failed melanoma, evaluating RP1 in combination with Opdivo ®  on track to release interim data in late 2022 Phase 2 development plan for RP2/3 to
January 4, 2022
WOBURN, Mass. , Jan. 04, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke , Chief Executive Officer of Replimune ,